Combretastatin A1 (Synonyms: CA1) |
Catalog No.GC43300 |
La combrétastatine A1 est un inhibiteur de la polymérisation des microtubules qui se lie au site de liaison à la colchicine de la tubuline. La combrétastatine A1 inhibe la voie Wnt/β-caténine par la désactivation de l'AKT médiée par la dépolymérisation de la tubuline. La combrétastatine A1 présente des effets anti-tumoraux et anti-vasculaires.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 109971-63-3
Sample solution is provided at 25 µL, 10mM.
Combretastatin A1 is a cis-stilbene originally isolated from C. caffrum that inhibits microtubule assembly (ID50 = 2 µM) by binding to the colchicine binding site on β-tubulin. It inhibits proliferation of hepatocellular carcinoma (IC50s = 9.2-728.2 nM) and other carcinoma cell lines (IC50s = 12.2-2,247 nM). Combretastatin A1 increases apoptosis of HepG2 cells in a GSK3β-dependent manner by decreasing the levels of MCL-1 and β-catenin. It inhibits tumor growth in a hepatocellular carcinoma mouse xenograft model when administered at doses of 2 or 4 mg/kg for 4 weeks. It also enhances the effects of carboplatin , paclitaxel , and cisplatin in murine models of cancer. Combretastatin A1 decreases functional vascular volume within hours in a well-vascularized murine colon adenocarcinoma model.
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *